INTS
INTENSITY THERAPEUTICS, INC.
NASDAQ · Healthcare · Biotechnology · US
$3.50
+3.55%Price chart
Oct 6Oct 9Oct 14Oct 19Oct 22Oct 27Oct 30Nov 4
Key dataNov 4, 2026
Open$3.50
From 52W high−76.27%
Volume2024.00
Market cap$11.43M
P/E (TTM)—
P/S (TTM)—
Div yield—
Key dataNov 4, 2026
Open
$3.50
From 52W high
−76.27%
Volume
2024.00
Market cap
$11.43M
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−0.2x
P/E (TTM)
—
RSI (14)
51.7
MomentumView details →
1D Return
+3.55%
YTD Return
−65.89%
SummaryUpdated Jun 1, 2026
Intensity Therapeutics, Inc. (NASDAQ:INTS) is a clinical-stage biotechnology company founded in 2012 and headquartered in Westport, Connecticut. The company went public in June 2023 and focuses on developing innovative cancer treatments for solid tumors. Intensity Therapeutics operates in the oncology drug development space, with its lead product candidate currently in Phase 2 clinical trials for treating various refractory solid tumors including pancreatic, colon, bile duct, and other challenging cancers.
Similar companies
Latest newsMore news →
Intensity Therapeutics announced that it will report third-quarter 2026 financial results before the market opens on November 5, 2026, and hold a conference call at 8:00 a.m. ET to review the results and provide a corporate update.5d agoIntensity Therapeutics, Inc. held its Q2 2026 earnings call on August 11, 2026.85d ago